Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 265

1.

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.

Romero A, Acosta-Eyzaguirre D, Sanz J, Moreno F, Serrano G, Díaz-Rubio E, Caldés T, Garcia-Saenz JÁ.

Transl Res. 2015 Apr 27. pii: S1931-5244(15)00136-X. doi: 10.1016/j.trsl.2015.04.010. [Epub ahead of print]

PMID:
26001593
2.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

Sastre J, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Grávalos C, Safont MJ, Martínez Villacampa M, Llovet P, Dotor E, Díaz-Rubio E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2015 May 8. pii: S0959-8049(15)00349-4. doi: 10.1016/j.ejca.2015.04.013. [Epub ahead of print]

PMID:
25963019
3.

BRCA1 Alternative splicing landscape in breast tissue samples.

Romero A, García-García F, López-Perolio I, Ruiz de Garibay G, García-Sáenz JA, Garre P, Ayllón P, Benito E, Dopazo J, Díaz-Rubio E, Caldés T, de la Hoya M.

BMC Cancer. 2015 Apr 3;15:219. doi: 10.1186/s12885-015-1145-9.

4.

New challenges in kidney cancer management: integration of surgery and novel therapies.

Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL.

Curr Treat Options Oncol. 2015 Mar;16(3):337. doi: 10.1007/s11864-015-0337-5.

PMID:
25782687
5.

Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.

Sotelo MJ, García-Sáenz JA, Manso L, Moreno F, Ciruelos E, Callata HR, Mendiola C, Cabezas S, Ghanem I, Díaz-Rubio E.

J Cancer Res Ther. 2014 Oct-Dec;10(4):967-72. doi: 10.4103/0973-1482.138017.

6.

Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors.

Veganzones S, Maestro ML, Rafael S, de la Orden V, Vidaurreta M, Mediero B, Espantaleón M, Cerdán J, Díaz-Rubio E.

Tumour Biol. 2015 May;36(5):3853-61. doi: 10.1007/s13277-014-3027-1. Epub 2015 Jan 10.

PMID:
25576161
7.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E, García-Alfonso P, Gallego-Plazas J, Lopez C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Díaz-Rubio E.

Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15.

PMID:
25515656
8.

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

Rivera F, Massutí B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de Paredes ML, Manzano JL, Galán M, Alsina M, Yuste Izquierdo AL, López C, Díaz-Rubio E, Conde V, Reboredo M, Cano MT, Pachón V, Aranda E.

Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.

PMID:
25491381
9.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ.

J Clin Oncol. 2015 Jan 1;33(1):22-8. doi: 10.1200/JCO.2014.56.5887. Epub 2014 Nov 10.

PMID:
25385741
10.

Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.

Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.

Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.

PMID:
25342642
11.

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.

Hernández-Prieto S, Romera A, Ferrer M, Subiza JL, López-Asenjo JA, Jarabo JR, Gómez AM, Molina EM, Puente J, González-Larriba JL, Hernando F, Pérez-Villamil B, Díaz-Rubio E, Sanz-Ortega J.

Clin Transl Oncol. 2015 Apr;17(4):330-8. doi: 10.1007/s12094-014-1235-1. Epub 2014 Oct 10.

PMID:
25301404
12.

Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib.

Cabezas-Camarero S, Puente J, Manzano A, Corona JA, González-Larriba JL, Bernal-Becerra I, Sotelo M, Díaz-Rubio E.

Anticancer Drugs. 2015 Jan;26(1):112-6. doi: 10.1097/CAD.0000000000000150.

PMID:
25075797
13.

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Camps-Herrero C, Paz-Ares L, Codes M, López-López R, Antón-Torres A, Gascón-Vilaplana P, Guillem-Porta V, Carrato A, Cruz-Hernández JJ, Caballero-Díaz C, Blasco-Cordellat A, Moreno-Nogueira JA, Díaz-Rubio E.

Clin Transl Oncol. 2014 Oct;16(10):914-20. doi: 10.1007/s12094-014-1170-1. Epub 2014 Jun 13.

PMID:
24924625
14.

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 May 28;20(20):6092-101. doi: 10.3748/wjg.v20.i20.6092. Review.

15.

BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X.

Garre P, Martín L, Sanz J, Romero A, Tosar A, Bando I, Llovet P, Diaque P, García-Paredes B, Díaz-Rubio E, de la Hoya M, Caldés T.

Clin Genet. 2015 Jun;87(6):582-7. doi: 10.1111/cge.12427. Epub 2014 Jun 18.

PMID:
24814045
16.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. Review.

17.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-Foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E.

Clin Transl Oncol. 2014 Oct;16(10):865-78. doi: 10.1007/s12094-014-1177-7. Epub 2014 Apr 12. Review.

PMID:
24728654
18.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
19.

Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.

Colombo M, Blok MJ, Whiley P, Santamariña M, Gutiérrez-Enríquez S, Romero A, Garre P, Becker A, Smith LD, De Vecchi G, Brandão RD, Tserpelis D, Brown M, Blanco A, Bonache S, Menéndez M, Houdayer C, Foglia C, Fackenthal JD, Baralle D, Wappenschmidt B; kConFaB Investigators, Díaz-Rubio E, Caldés T, Walker L, Díez O, Vega A, Spurdle AB, Radice P, De La Hoya M.

Hum Mol Genet. 2014 Jul 15;23(14):3666-80. doi: 10.1093/hmg/ddu075. Epub 2014 Feb 25.

PMID:
24569164
20.

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.

Fernández-Marcelo T, Frías C, Pascua I, de Juan C, Head J, Gómez A, Hernando F, Jarabo JR, Díaz-Rubio E, Torres AJ, Rouleau M, Benito M, Iniesta P.

J Exp Clin Cancer Res. 2014 Feb 15;33:19. doi: 10.1186/1756-9966-33-19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk